Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir
Viruses · 2024
DOI: 10.3390/v16071162 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Ingrid A Beck und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA. Hauptthemen laut MEDLINE: Oxazines, HIV-1, Heterocyclic Compounds, 3-Ring, Piperazines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
The WHO currently recommends dolutegravir (DTG)-based ART for persons living with HIV infection in resource-limited-settings (RLS). To expand access to testing for HIV drug resistance (DR) to DTG in RLS, we developed probes for use in the oligonucleotide ligation assay (OLA)-Simple, a near-point of care HIV DR kit. Genotypic data from clinical trials and case reports were used to determine the mutations in HIV-1 integrase critical to identifying individuals with DTG-resistance at virologic failure of DTG-based ART. Probes to detect G118R, Q148H/K/R, N155H and R263K in HIV-1 subtypes A, B, C, D and CRF01_AE were designed using sequence alignments from the Los Alamos database and validated using 61 clinical samples of HIV-1 subtypes A, B, C, D, CRF01_AE genotyped by PacBio (n = 15) or Sanger (n = 46). Initial OLA probes failed to ligate for 16/244 (6.5%) codons (9 at G118R and 7 at Q148H/K/R). Probes revised to accommodate polymorphisms interfering with ligation at codons G118R and Q148R reduced indeterminates to 3.7% (5 at G118R and 4 at Q148H/K/R) and detected DTG-mutations with a sensitivity of 96.5% and 100% specificity. These OLA DTG resistance probes appear highly sensitive and specific across HIV-1 subtypes common in RLS with high burden of HIV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.
- Department of Bioengineering, University of Washington, Seattle, WA 98195, USA.
- Departments of Medicine, Pediatrics and Laboratory Medicine, University of Washington, Seattle, WA 98195, USA.
ORCID-Profile: Nuttada Panpradist, Lisa M Frenkel
Förderung
- NIAID NIH HHS
- NIH HHS
- NICHD NIH HHS
- National Institutes of Health
- the National Institutes of Health (NIH)
Zitieren
APA
Beck, I. A., Boyce, C. L., Bishop, M. D., Vu, Y. L., Fung, A., Styrchak, S., Panpradist, N., Lutz, B. R., & Frenkel, L. M. (2024). Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir. Viruses. https://doi.org/10.3390/v16071162
Vancouver
Beck IA, Boyce CL, Bishop MD, Vu YL, Fung A, Styrchak S, et al. Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir. Viruses. 2024. doi:10.3390/v16071162
BibTeX
@article{Beck2024,
author = {Beck, Ingrid A and Boyce, Ceejay L and Bishop, Marley D and Vu, Yen L and Fung, Amanda and Styrchak, Sheila and Panpradist, Nuttada and Lutz, Barry R and Frenkel, Lisa M},
title = {Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16071162}
}
EUVIMED